Portuguese 
English 
Spanish 
3 min of reading 
The New Fiocruz Factory in Curitiba Will Develop Components for Vaccines and Advanced Cancer Therapies
The mayor of Curitiba, Rafael Greca, was present on Friday, the 5th, at the Clube Curitibano for the celebration of the anniversary of IBMP (Institute of Molecular Biology of Paraná), founded by the Oswaldo Cruz Foundation (Fiocruz) in collaboration with the Government of the State of Paraná to develop activities related to biotechnology, innovation, and industrial production of health solutions at the factory.
Mayor Greca also emphasized the work of IBMP throughout the pandemic and the investment in the new biotechnology factory in the Industrial City of Curitiba (CIC), which will develop inputs for vaccines and advanced therapies in cancer.
Also present at the event was the vice president of production and health innovation at Fiocruz, Marco Aurélio Krieger, who represented the company’s president, Nísia Veronica Trindade Lima. Marco highlighted the role of IBMP during the Covid-19 pandemic: “The biotechnology institute had an exemplary performance, being recognized by society in Paraná and Brazil. IBMP is currently considered the crown jewel of Fiocruz, which now views this operation as a model for its own development,” he commented.
-
The radish leaf that almost everyone throws away has more polyphenols, flavonoids, and fiber than the consumed root, and a 2025 study showed that the leaf contains compounds that protect the intestine, combat inflammation, and may inhibit the growth of cancer cells.
-
A planet that seemed to defy the laws of physics has intrigued scientists for decades, until the James Webb revealed what is really affecting Saturn’s rotation.
-
For the first time in history, the Brazilian Air Force conducted a highly complex inspection on the C-99 jet independently, without relying on foreign companies, marking a new level of logistical autonomy and operational sovereignty.
-
Beet greens that end up in the trash in many kitchens contain a high concentration of antioxidants, and a 2025 study shows that extracts may have even more potent activity when transformed into microparticles.
IBMP Developed Just Over 35 Million Tests During the Pandemic
Since the beginning of the pandemic, IBMP has developed at its biotechnology factory more than 35 million rapid tests delivered to the SUS, through Fiocruz, and, in record time, acted in the development and production of the molecular test using biotechnology, which was used as a confirmatory test for the first case in Brazil. Additionally, IBMP established the molecular testing factory for Covid-19 in Paraná, responsible for processing over 3.5 million samples.
“IBMP was created with the DNA of innovation, which has been a hallmark of Fiocruz since its foundation. Innovation is a systemic process, which needs to be fueled with support, protection, and access to markets. Curitiba has everything to be a hub for science and biotechnology. By 2023, we will double the capacity of the factories, with investments of around R$ 150 million, including two or three new plants, producing strategic inputs for vaccines and cancer therapies that are currently not produced in Brazil and rely on imports,” stated Pedro Ribeiro Barbosa, president of IBMP.
Last Friday, IBMP celebrated its foundation, established in 1999, and the implementation of the new factory in Curitiba, in 2009. The production unit was the first outside of Rio de Janeiro for Fiocruz, which last Thursday, the 4th, celebrated the 150th anniversary of the birth of scientist Oswaldo Cruz, its founder.
New Fiocruz Factory in Curitiba
IBMP is acquiring the area from Curitiba S.A. at Parque da Saúde CIC to install a new factory for the production of components for vaccines and advanced therapies in cancer.
In total, there will be two biotechnology units in CIC. One will be dedicated to the development and production of vaccines and inputs for advanced therapies based on gene therapy, which will use vectors such as molecules of DNA from the infectious agent into the human cell to create antibodies. The other unit will be dedicated to the production of new medications based on biotechnology for autoimmune diseases based on therapeutic proteins, in a structure that is unprecedented in the country.
Also present at the event last Friday were the Secretary of State for Health, Cesar Augusto Neves Luiz, the president of the Curitiba Agency for Development and Innovation, Cris Alessi, the vice president of management and institutional development at Fiocruz, Mario Santos Moreira, the president of Tecpar, Jorge Augusto Callado, the director of the Carlos Chagas/Fiocruz institute, Stênio Fragoso, and the other directors of IBMP and collaborators from the institute.
Seja o primeiro a reagir!